key: cord-1054698-vlc7u2as
authors: Labella, Marina; Céspedes, Jose Antonio; Doña, Inmaculada; Shamji, Mohamed H.; Agache, Ioana; Mayorga, Cristobalina; Torres, Maria José
title: The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID‐19 vaccine
date: 2021-10-31
journal: Allergy
DOI: 10.1111/all.15148
sha: 85e6b327d5d2a7d1505e2d9543beab06a1f3456b
doc_id: 1054698
cord_uid: vlc7u2as

BACKGROUND: mRNA‐based COVID‐19 vaccines have been reported to induce hypersensitivity reactions (HSR) in a small number of individuals. We aimed to evaluate the real‐world incidence of the BNT162b2 mRNA COVID‐19 vaccine HSR and to determine the value of the basophil activation test (BAT) in the allergological workup of patients reporting these reactions. METHODS: We prospectively enrolled patients with a clinical history indicative of HSR to the BNT162b2 mRNA COVID‐19 vaccine. The allergological workup included skin testing (STs) and BAT with polyethylene glycol (PEG) and the vaccine. In those with negative allergy assessments, the administration of the second dose of the BNT162b2 mRNA COVID‐19 vaccine was offered. RESULTS: Seventeen adults were included. Eleven cases (64.7%) tested negative in the allergological workup and tolerated the re‐administration of the second dose of the vaccine and considered non‐allergic. Six cases (35.3%) were considered allergic and classified into three groups: 2 subjects displayed positive STs and/or BAT to PEG (Group A), two individuals displayed positive BAT to the vaccine (Group B), and in 2 patients with moderate or severe reactions, the culprit was not identified, tested negative to STs and BAT to both PEG and vaccine (Group C). We further evaluated the value of BAT when the results were positive to the vaccine and negative to PEG by performing BAT in controls groups, finding positive BAT results in 50% of controls, all of them recovered from COVID‐19 infection. In contrast, BAT was negative in patients who had not suffered from COVID‐19 disease. CONCLUSIONS: BAT can be used as a potential diagnostic tool for confirming allergy to PEG excipient but not to the vaccine as a positive result in BAT may indicate a past COVID‐19 infection instead of an allergy.

The declaration of the pandemic induced by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in March 2020 by the World Health Organization (WHO) has led to an unprecedented challenge for healthcare systems. 1, 2 The development of mRNA-based vaccines to prevent infection with SARS-CoV-2 is a landmark achievement of basic, translational, clinical and regulatory science. 3, 4 Following regulatory approval, hypersensitivity reactions (HSRs) were reported in a small number of subjects receiving the vaccine, which resulted in public distress and a loss of confidence in vaccination safety. 5 Regulatory agencies introduced a summary of product characteristics, which included potential HSRs to mRNA-based vaccines and promptly issued recommendations on the avoidance of a second dose following a HSR to the first dose.

The European Academy of Allergy and Clinical Immunology (EAACI) issued recommendations 6, 7 for the safe administration of COVID-19 vaccines, reviewed the allergic adverse reactions that can potentially occur after vaccination, and evaluated all vaccine components with allergenic potential. 8 HSRs to customary anti-infectious vaccines have been estimated to account for 1-5 per million administered doses, 6 with IgE-mediated HSRs (anaphylaxis) to vaccines occurring in less than 1 case per million applications. For the BNT162b2 mRNA COVID-19 vaccine, 11.1 cases occurred per million administered doses. 9 The underlying immunological mechanisms of the rare severe allergic reactions to the COVID-19 vaccines are poorly understood and need to be investigated. Immediate reactions to vaccines may be induced by excipients that act as preservatives, stabilisers or adjuvants in contrast to other types of drug allergy, where reactions are usually related to the active drug. [10] [11] [12] Unless the patient has a history of an allergic reaction to any of the vaccine excipients or a severe allergic reaction to the first dose of COVID-19 vaccine, there is no contraindication to COVID-19 vaccines administration, nor HSR assessment is needed 8, 12, 13 The diagnostic workup in patients suspected of HSR includes in vivo skin tests (STs) and or in vitro approach, such as a basophil activation test (BAT). This evaluation is needed before excluding patients with suspected HSRs from receiving the vaccine and thus putting them at risk of severe COVID-19 infection. 6 In this work, we evaluate the accuracy of an allergological workup, including BAT, to manage patients with HSRs to the first dose of the BNT162b2 mRNA COVID-19 vaccine for the safe administration of the second dose in order to achieve complete vaccination. Our results confirm that BAT is a potential tool for the diagnosis of HSRs to PEG excipient. However, BAT is not helpful to determine an allergy to the vaccine, as a positive result in BAT may indicate a past COVID-19 infection instead of an allergy.

This study enrolled 17 adult patients referred to the Allergy Unit of the Regional University Hospital of Málaga starting with January 2021 to evaluate a possible HSR to the SARS-CoV-2 vaccine (BioNTech,

The allergological workup of the patients reporting reactions after the vaccine administration is crucial to achieve a precise diagnosis. BAT can be used as a potential diagnostic tool for confirming allergy to PEG excipient. A positive result in BAT to COVID-19 BNT162b vaccine may indicate a past COVID-19 infection instead of an allergy.

Pfizer, USA). The Allergy Unit is a tertiary public referral centre for all drug allergy evaluation in an area of 1,900,000 inhabitants.

Reactions were classified into immediate reactions (IRs) or non-immediate (NIRs), depending on whether the symptoms appeared within 1-6 h or later than 1 h, respectively, after administering the dose. 14 Reaction severity was classified as grade 1 (mild: skin and subcutaneous tissues); grade 2 (moderate: symptoms suggesting respiratory, cardiovascular, or gastrointestinal involvement); and grade 3 (severe: hypoxia, hypotension or neurologic compromise). 15 The allergological workup started with a comprehensive clinical history performed according to the EAACI questionnaire, 16 

SPTs were carried out as previously described 18 using the vaccine Comirnaty (BioNTech, Pfizer, USA) 1:1, PEG 1500 (Roxall, Biscay, Spain) using 0.1%, 1% and 10% sequentially tested, and PEG 3350 (Movicol ® ) (Norgine, Madrid, Spain) at 55 mg/ml. If negative, IDTs were carried out 18 using PEG 1500 (Roxall, Biscay, Spain) at 0.01%, and PEG 3350 (Movicol ® ) (Norgine, Madrid, Spain) at 0.55 and 5.5 mg/ml as recommended. 12, [19] [20] [21] Positivity criteria for SPTs were the development of a wheal larger than 3 mm surrounded by erythema, with a negative response to the control saline and for IDTs were an increase greater than 3 mm in the diameter of the initial wheal area surrounded by erythema. 22 

In subjects with NIRs and negative STs to PEG and vaccine, the second dose of BNT162b2 was administered at the vaccination point. 

Patients from the cross-sectional study and those from the longitudinal study were evaluated with BAT. BAT was performed as previously described with some modifications. 24 One hundred µL of 

Description of the quantitative variable was performed, including the median and interquartile range. Differences between qualitative variables were analysed by the chi-square test (non-related samples) and the McNemar test (related samples).

Mann-Whitney U test (non-related samples) and by Wilcoxon test (related samples). All statistical analyses were carried out using the software package GraphPad PRISM v7. A value of p < .05 was considered statistically significant.

Seventeen patients were sent for evaluation to our unit (Table 1 and Table S1 ). One case was confirmed by positive SPTs to PEG (Pt 1). Five cases with negative STs reported unequivocal allergic symptoms after the first dose vaccine administration. Despite the negative SPTs, they declined the administration of the second dose of BNT162b2, and one patient (Pt4) received Vaccine Janssen (Janssen-Cilag International NV, Beerse, Belgium) with good tolerance. The description of these patients is shown in (Table 2) .

Interestingly, 4 out of 6 were health workers who are subjects at 

For BAT studies, we first performed ROC curves for both PEG and vaccine. The area under curve (AUC) for PEG at 100 µg/ ml was 0.7154 (p = .2097), for vaccine at 10 µg/ml was 0.6868 (p = .1062) and vaccine at 1 µg/ml was 0.6593 (p = .1682).

Therefore, we selected as cut-off points 3 for PEG at 100µg/ml, and 2 and 2.5 for vaccine at 10 µg/ml and 1 µg/ml, respectively ( Figure S1 ).

In the group of patients referred for suspected HSR to BNT162b2, we found 2 cases with BAT positive to PEG and vaccine BNT162b2

(Pt 1 and Pt 2) and 2 cases with BAT positive only to the vaccine (Pt 3

and Pt 4) ( vaccine (Pt 5 and Pt 6). Therefore, we were not able to confirm the causal agent (Table 2) . Table 2 ).

We further evaluated BAT value for the diagnosis of HSR to the BNT162b2 vaccine by conducting BAT (with PEG and with vaccine) in four different control groups (Table 4 ). Positive BAT results to the vaccine BNT162b2 were found in 5 out of 10 controls (50%); all of them recovered from COVID-19 infection (3 C-NV and 2 C-V). In controls who did not suffer COVID-19 (NC-V and NC-NV), BAT to BNT162b2 was negative in all cases ( Figure 2 ). In all controls, BAT to PEG was negative. In all subjects, including patients and controls (C-NV and C-V), positive BAT with either PEG or Vaccine, wortmannin experiments confirmed that basophil activation was mediated by IgE. (Figures 3 and 4 ).

In the follow-up of the 30 subjects receiving the BNT162b2 vaccine, the BAT results indicated no differences in the SI to either PEG or BNT162b2 before and at different time points after the administration of the first and the second dose (p > .05). ( Figure 5 ).

This study reports on the value of the allergological workup for patients with reactions to the first COVID-19 vaccine dose, with a particular emphasis on BAT. It also evaluates the immunological profile and safety of the COVID-19 vaccine longitudinally up to 3 months after the second dose, using BAT.

The diagnosis of HSR to BNT162b2 due to PEG 2000 was confirmed by BAT in only 2 out of 17 (11.7%) patients reporting a reaction after vaccination. PEG is an excipient contained in the mRNA vaccines as well as in multiple drugs and cosmetic products.

Although allergy to PEG is rare, it has been previously described as a compound that can induce severe allergic reactions 21, 27 ; therefore, the precise diagnosis is crucial. The correct diagnosis of PEG HSR is important due to the widespread use of this molecule which behaves as a 'hidden' allergen. 28 Positive STs (SPTs and IDTs) and BAT to PEG has been reported in small series and cases reports, raising the possibility of IgE-mediated type HSRs. 10, 29 This study supports BAT to PEG as a valuable tool to exclude the diagnosis of PEG allergy. In our study, we did not find any case with positive SPTs to vaccine. Therefore, in those patients reporting suspected HSR to the vaccine in which we have ruled out allergy to PEG by STs and BAT, the administration of the second dose of the vaccine under medical supervision and using is the only method to confirm or exclude the diagnosis of HSR. 33, 34 Nevertheless, this procedure is not risk-free.

In cases with moderate/severe and suggestive allergic reactions Based on the data obtained from our study, we propose an algorithm for the diagnostic approach of suspected allergic reaction to the COVID-19 BNT162b2 vaccine, as described in (Figure 6 ).

In conclusion, HSRs due to BNT162b2 vaccines are very rare, and their over-diagnosis must be avoided to ensure a complete and efficient vaccination. Therefore, the allergological workup of the patients reporting reactions after the vaccine administration is crucial to achieve a precise diagnosis. BAT is a promising tool for confirming the diagnosis of HSRs to excipient PEG. However, BAT has shown not to be helpful to determine an allergy to the vaccine, as a positive result in BAT probably indicates a past SARS-COV-2 infection rather than vaccine sensitization. The administration of the second dose of BNT162b2 under strict clinical supervision and in incremental doses is recommended in patients with suspected HSRs when PEG allergy has been previously excluded.

We thank Ms. Claudia Corazza for her help with the English version of the manuscript and Verónica Prados for her help in technical support in flow cytometry methods.

No author has any conflicts of interest to disclose. 

Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-a report of the European Academy of Allergy and Clinical Immunology (EAACI)

SARS-CoV-2, COVID-19, skin and immunology -what do we know so far?

Maintaining safety with SARS-CoV-2 vaccines

Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19

Immunemediated adverse reactions to vaccines

EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines

ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines -an EAACI-ARIA Position Paper

Vaccines and allergic reactions: the past, the current COVID-19 pandemic, and future perspectives

COVID-19 vaccine anaphylaxis: IgE, complement or what else? A reply to

Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized

Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol?

COVID-19 vaccine-associated anaphylaxis and allergic reactions: consensus statements of the KAAACI urticaria/angioedema/anaphylaxis working group

A compendium answering 150 questions on COVID-19 and SARS-CoV-2

International Consensus on drug allergy

Clinical features and severity grading of anaphylaxis

Drug hypersensitivity: questionnaire

COVID-19 pandemic: practical considerations on the organization of an allergy clinic-an EAACI/ ARIA Position Paper

General considerations for skin test procedures in the diagnosis of drug hypersensitivity

Vaccine allergy: evidence to consider for COVID-19 vaccines

Optimizing investigation of suspected allergy to polyethylene glycols

Polyethylene glycol-induced systemic allergic reactions (anaphylaxis)

Diagnosis of immediate allergic reactions to beta-lactam antibiotics

Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations

The diagnostic interpretation of basophil activation test in immediate allergic reactions to betalactams

The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease

In vitro evaluation of IgEmediated hypersensitivity reactions to quinolones

Immediate-type hypersensitivity to polyethylene glycols: a review

Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine

Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation

Safety of new mrna vaccines against covid-19 in severely allergic patients

Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in PEG allergic patients

In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper

Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy

Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Heterologous vaccine regimens against COVID-19

The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID-19 vaccine